ConductScience.org, home

Paper12372957

Tranilast slows the progression of advanced diabetic nephropathy.

Soma J and 4 others. Nephron, 2002. Cited by 50 papers, by iCite.

Cite this record

ConductScience Library. Tranilast slows the progression of advanced diabetic nephropathy. Papers, record 12372957. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/12372957

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Tranilast slows the progression of advanced diabetic nephropathy.
PubMed
Journal
Nephron
PubMed
Year
2002
PubMed
Publication types
Clinical Trial, Journal Article
PubMed
Citations, by iCite
50
iCite
Relative citation ratio, by iCite
1.1
iCite
Revised in PubMed
2017-11-01
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Soma JJun
2Sugawara TTakashi
3Huang YDYee-Der
4Nakajima JJun
5Kawamura MMinoru

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Anti-Inflammatory Agents, Non-SteroidalMajor topic
Diabetic NephropathiesMajor topic
ortho-AminobenzoatesMajor topic
Adult
Aged
Collagen Type IV
Creatinine
Diabetes Mellitus, Type 2
Disease Progression
Female
Humans
Male
Middle Aged
Proteinuria
Treatment Outcome

Source PubMed

Download CSV of topics

Cited by19

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 50 citations.

PMIDTitleJournalYearIn PapersSource
42292355NLR inflammasome pathways: key targets for pathogenesis and therapy of metabolic diseases.Front Immunol2026https://conductscience.org/library/papers/42292355PubMed
40415299The NLRP3-P2X7 Axis and Cytokine Crosstalk in Alzheimer's Disease: Mechanisms, Implications, and Therapeutic Opportunities.CNS Neurol Disord Drug Targets2025https://conductscience.org/library/papers/40415299PubMed
37211853To Explore the Putative Molecular Targets of Diabetic Nephropathy and their Inhibition Utilizing Potential Phytocompounds.Curr Med Chem2024https://conductscience.org/library/papers/37211853PubMed
36960868Inhibitors of the NLRP3 inflammasome pathway as promising therapeutic candidates for inflammatory diseases (Review).Int J Mol Med2023https://conductscience.org/library/papers/36960868PubMed
36142794Recent Advances in the Emerging Therapeutic Strategies for Diabetic Kidney Diseases.Int J Mol Sci2022https://conductscience.org/library/papers/36142794PubMed
27558558Immunity and inflammation in diabetic kidney disease: translating mechanisms to biomarkers and treatment targets.Am J Physiol Renal Physiol2017https://conductscience.org/library/papers/27558558PubMed
26847481Hypoxia: The Force that Drives Chronic Kidney Disease.Clin Med Res2016https://conductscience.org/library/papers/26847481PubMed
26421309Potential Renoprotective Agents through Inhibiting CTGF/CCN2 in Diabetic Nephropathy.J Diabetes Res2015https://conductscience.org/library/papers/26421309PubMed
25972814HIPK2 is a new drug target for anti-fibrosis therapy in kidney disease.Front Physiol2015https://conductscience.org/library/papers/25972814PubMed
25884585Valsartan blocks thrombospondin/transforming growth factor/Smads to inhibit aortic remodeling in diabetic rats.Diagn Pathol2015https://conductscience.org/library/papers/25884585PubMed
24662433Novel targets of antifibrotic and anti-inflammatory treatment in CKD.Nat Rev Nephrol2014https://conductscience.org/library/papers/24662433PubMed
23179685Molecular targets for treatment of kidney fibrosis.J Mol Med (Berl)2013https://conductscience.org/library/papers/23179685PubMed
23071743A purpose-synthesised anti-fibrotic agent attenuates experimental kidney diseases in the rat.PLoS One2012https://conductscience.org/library/papers/23071743PubMed
22566893Different roles of mast cells in obesity and diabetes: lessons from experimental animals and humans.Front Immunol2012https://conductscience.org/library/papers/22566893PubMed
22278738Tranilast ameliorates impaired hepatic functions in Schistosoma mansoni-infected mice.Inflammopharmacology2012https://conductscience.org/library/papers/22278738PubMed
22073152Predicting in vivo anti-hepatofibrotic drug efficacy based on in vitro high-content analysis.PLoS One2011https://conductscience.org/library/papers/22073152PubMed
21782136Off the beaten renin-angiotensin-aldosterone system pathway: new perspectives on antiproteinuric therapy.Adv Chronic Kidney Dis2011https://conductscience.org/library/papers/21782136PubMed
21659774Antifibrotic treatment and other new strategies for improving renal outcomes.Contrib Nephrol2011https://conductscience.org/library/papers/21659774PubMed
19455178Emerging therapies for chronic kidney disease: what is their role?Nat Rev Nephrol2009https://conductscience.org/library/papers/19455178PubMed

Download CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
TGFB17040PubTator's text mininghttps://conductscience.org/library/genes/7040NCBI Gene
UPP17378PubTator's text mininghttps://conductscience.org/library/genes/7378NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/12372957

GET https://conductscience.org/api/papers/v1/12372957/authors